STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Why this matters: health reporting relevant to everyday decisions and well-being.
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.&#x A0; Up until last year, CREATE was known as Myeloid Therapeutics. The startup was cofounded by noted writer and oncologist Siddhartha Mukherjee to develop better CAR-T therapies using a type of immune agent called myeloid cells, ideally to better attack solid tumors. The company rebranded last fall and, like many other oncology CAR-T companies, expanded into autoimmune disease research.  Now, CREATE has raised another $122 million from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and others, the biotech told STAT exclusively.Continue to STAT+ to read the full story…